Traitement Cancer du foie en Israël — recevez 3 correspondances personnalisées de cliniques

Israeli oncology centres report success rates between 85% and 95% for surgical removal of early-stage liver tumours. Leading facilities like Sourasky Medical Center maintain a 90% overall oncology treatment success rate. High-volume surgery and precision techniques help maintain these surgical outcomes.

• Procedure efficacy: Liver resection achieves 90% primary effectiveness for localized primary or metastatic tumours.
• Hepatic recovery: Institutions like Hadassah Medical Center report 80% post-surgical liver function recovery rates.
• Surgical volume: Sheba Medical Center manages 6,500+ liver cases annually to optimise survival curves.
• Expertise level: Top surgeons such as Dr Ido Nachmany specialise in robotic and laparoscopic liver management.

Bookimed Expert Insight: Israeli surgical success often stems from aggressive conversion therapies for complex cases. Programs like Hepatic Artery Infusion convert 80% of inoperable tumours into resectable ones. This means patients previously told they are ineligible for surgery may find options at high-volume centres like Sheba or Sourasky.

Patient Consensus: Patients emphasize that success involves long-term monitoring rather than just clinic discharge. They suggest arranging local follow-up in Australia before traveling to Israel, as scan-based checks for 24 months are the true test of surgery.

Patients choose Israel to confirm liver cancer diagnoses due to ultra-precise histopathology re-evaluations and multidisciplinary tumor boards. Centres like Sheba Medical Center use advanced PET/CT imaging and multi-omics testing. Australian patients gain clarity on staging through experts trained at prestigious US institutions within 3 to 4 days.

• Histopathology revision: Experts re-examine existing biopsy slides to rule out staging errors or misdiagnoses.
• Advanced imaging: Clinics use high-resolution PET/MRI and 256-slice CT scans to find microscopic lesions.
• Multidisciplinary boards: Hepatologists and surgeons at Sourasky Medical Center review cases collectively for accuracy.
• Molecular profiling: Specialist labs map genetic markers to match tumours with targeted immunotherapy protocols.

Bookimed Expert Insight: Israeli oncology centres like Sheba and Sourasky manage massive patient volumes, treating over 1,800,000 people annually. This high-frequency exposure means their specialists, like Professor Ido Nachmany, see rare liver variants daily. For Australians, this volume-driven expertise often results in reinterpreted staging that may prevent unnecessary invasive surgeries.

Patient Consensus: Patients find the speed of bundled appointments for scans and pathology reviews provides immense psychological relief. They emphasize bringing original digital scans and biopsy slides to Israel to ensure a fast, fresh perspective on their condition.

Cirrhosis significantly restricts liver cancer treatment because it limits the liver's ability to process drugs and heal after surgery. Specialists in Israel use MELD or Child-Pugh scores to assess liver reserve. High-scoring cases often require liver-sparing therapies like radiofrequency ablation or chemoembolisation instead of major surgery.

• Treatment selection: Liver reserve determines eligibility for curative options like resection or transplant.
• Surgical risks: Scarring increases bleeding hazards and complicates recovery after tumour removal.
• Sparing techniques: Specialists use CyberKnife or ablation to treat tumours while protecting functional tissue.
• Drug metabolism: Impaired filtration requires precise chemo dosing to avoid toxicity and liver failure.

Bookimed Expert Insight: Israeli oncology centres like Sourasky often prefer local-regional therapies over systemic chemotherapy for cirrhotic patients. Data shows specialists there, such as Professor Ido Nachmany, specialise in robotic liver surgeries. These minimally invasive techniques help preserve the small amount of healthy liver tissue remaining in cirrhotic patients.

Patient Consensus: Patients note that liver function scores often dictate treatment more than the tumour size itself. They emphasize that while major surgery is frequently ruled out, alternatives like TACE or ablation in Israel provide effective, liver-sparing options.

A biopsy is not always required for liver cancer treatment in Israel. Following international guidelines, Israeli oncologists often diagnose hepatocellular carcinoma (HCC) using high-resolution imaging. This non-invasive approach is standard if patients have cirrhosis or chronic hepatitis and show specific vascular patterns on scans.

• Imaging diagnosis: Dynamic CT or MRI often confirms cancer via arterial-phase contrast uptake.
• Tumour markers: High Alpha-Fetoprotein levels combined with precise imaging can replace invasive needles.
• Biopsy criteria: Biopsies are necessary for non-cirrhotic patients or when imaging remains inconclusive.
• Seed avoidance: Skipping biopsies prevents tumour seeding and reduces risks like internal bleeding.

Bookimed Expert Insight: Israeli centres like Sourasky or Sheba often perform a histopathology revision for international cases. Patients should bring original pathology slides from Australia. This allows Israeli specialists to verify a previous biopsy without performing a second invasive procedure.

Patient Consensus: Patients in Israel note that doctors prefer using advanced imaging and blood markers to avoid biopsy risks. Many recommend disclosing any blood-thinning medications early to help the medical team safely plan diagnostic steps.

International patients typically stay in Israel between 4 days and 8 weeks. Quick diagnostics take 3 to 5 days. Minimally invasive liver procedures require 1 to 2 weeks. Complex surgeries or intensive therapies like CAR-T often need up to 2 months for safe recovery before flying.

• Diagnostic phase: Pre-treatment scans and biopsies usually take 2 to 4 days.
• Minimally invasive: Ablation or chemoembolisation stays range from 3 to 14 days.
• Surgical resection: Major liver surgery requires 2 to 3 weeks for clinical stability.
• Advanced therapies: Complex oncology treatments like CAR-T may require 4 to 8 weeks.

Bookimed Expert Insight: Israeli oncology centres like Sheba and Sourasky serve over 1.8 million patients annually. Their high case volume allows doctors to streamline pre-treatment tests. Australian patients can often start treatment within 72 hours of arrival. This speed helps many complete complex surgical resections well within the 90-day tourist visa limit.

Patient Consensus: Patients note that the first few days are busy with scans and specialist reviews. They emphasize waiting for a formal fit-to-fly clearance before booking return flights to Australia. The medical teams in Israel routinely provide discharge summaries to ensure smooth transition of care to local GPs.